InnoSilicon: Receives milestone payment of 39 million Hong Kong dollars from Menarini, completion of first patient dosing in collaboration project MEN2501.

On February 3rd, Yingxue Intelligence announced that the company has completed the first patient dosing in the Phase I clinical trial of the MEN2501 project licensed to the Menarini Group in January 2025. According to the cooperation agreement, Yingxue Intelligence has received a milestone payment of 39 million Hong Kong dollars from Menarini. MEN2501 is a highly differentiated small molecule inhibitor targeting the driver protein KIF18A, with preclinical data showing significant inhibitory activity against chromosomal instability cancers.